Proposed Part D rule changes could be bane to brand drugmakers
By Mari Serebrov
Tuesday, January 7, 2014
With an eye on the bottom line, the Centers for Medicare & Medicaid Services (CMS) is proposing a Part D rule change that would tip the formulary scale in favor of generics and, in time, biosimilars.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.